Claims
- 1. A method of detecting analytes, the method comprising
associating one or more detectors with one or more target samples, wherein the detectors each comprise a specific binding molecule, a carrier, and a block group, wherein the block group comprises blocks, and detecting the block group.
- 2. The method of claim 1, wherein the blocks have the same amount composition.
- 3. The method of claim 1, wherein the blocks do not all have the same amount composition.
- 4. The method of claim 1, wherein a plurality of detectors are associated with the one or more target samples, wherein the block group of each detector has a different composition of blocks.
- 5. The method of claim 4, wherein each block group has the same number of blocks.
- 6. The method of claim 4, wherein the block groups do not all have the same number of blocks.
- 7. The method of claim 4, wherein each block group has a different identity composition of blocks.
- 8. The method of claim 4, wherein the blocks have the same amount composition.
- 9. The method of claim 4, wherein the blocks do not all have the same amount composition.
- 10. The method of claim 4, wherein block groups that have the same identity composition of blocks have different amount compositions of blocks.
- 11. The method of claim 1, wherein the blocks are peptide nucleic acids.
- 12. The method of claim 1, wherein the blocks are capable of hybridizing specifically to an oligonucleotide reporter tag.
- 13. The method of claim 12, wherein the length of the oligonucleotide reporter tag is between 10 and 35 nucleotides long.
- 14. The method of claim 12, wherein the length of the oligonucleotide reporter tag is between 15 and 20 nucleotides long.
- 15. The method of claim 1, wherein the blocks are capable of being detected by a method selected from the group consisting of nuclear magnetic resonance, electron paramagnetic resonance, surface enhanced raman scattering, surface plasmon resonance, fluorescence, phosphorescence, chemiluminescence, resonance raman, microwave, mass spectrometry, mass spectrometry electrophoresis chromatography, and any combination of these.
- 16. The method of claim 1, wherein the blocks are capable of being detected through MALDI-TOF spectroscopy.
- 17. The method of claim 1, wherein the blocks are isobaric blocks.
- 18. The method of claim 17, wherein a plurality of detectors are associated with one or more target samples, wherein the blocks of each detector are different.
- 19. The method of claim 18, wherein all of the blocks of all of the detectors have the same mass-to-charge ratio.
- 20. The method of claim 19, wherein the blocks are altered by altering their mass, charge, or both, wherein the altered forms of the blocks are distinguished via differences in the mass-to-charge ratio of the altered forms of the blocks.
- 21. The method of claim 1, wherein the carrier is selected from the group consisting of beads, liposomes, microparticles, nanoparticles, and branched polymer structures.
- 22. The method of claim 1, wherein the carrier is a bead.
- 23. The method of claim 1, wherein the carrier is a liposome or microbead.
- 24. The method of claim 23, wherein the liposomes are unilamellar vesicles.
- 25. The method of claim 24, wherein the vesicles have an average diameter of 150 to 300 nanometers.
- 26. The method of claim 21, wherein the liposome has an internal diameter of 200 nanometers.
- 27. The method of claim 1, wherein the carrier is a dendrimer.
- 28. The method of claim 27, wherein the dendrimer is contacting a macromolecule selected from the group consisting of DNA, RNA, and PNA.
- 29. The method of claim 28, wherein the macromolecule is an oligonucleotide between 20 and 300 nucleotides in length.
- 30. The method of claim 1, wherein the specific binding molecule is selected from the group consisting of antibodies, ligands, binding proteins, receptor proteins, haptens, aptamers, carbohydrates, synthetic polyamides, and oligonucleotides.
- 31. The method of claim 1, wherein the specific binding molecule is a binding protein.
- 32. The method of claim 31, wherein the binding protein is a DNA binding protein.
- 33. The method of claim 31, wherein the DNA binding protein contains a motif selected from the group consisting of a zinc finger motif, leucine zipper motif, and helix-turn-helix motif.
- 34. The method of claim 33, wherein the specific binding molecule is an oligonucleotide.
- 35. The method of claim 33, wherein the oligonucleotide is between 10 and 40 nucleotides in length.
- 36. The method of claim 33, wherein the oligonucleotide is between 16 and 25 nucleotides in length.
- 37. The method of claim 33, wherein the oligonucleotide is a peptide nucleic acid.
- 38. The method of claim 33, wherein the oligonucleotide forms a triple helix with the target sequence.
- 39. The method of claim 33, wherein the oligonucleotide comprises a psoralen derivative capable of covalently attaching the oligonucleotide to the target sequence.
- 40. The method of claim 1, wherein the specific binding molecule is an antibody.
- 41. The method of claim 40, wherein the antibody binds a protein.
- 42. The method of claim 1, wherein the blocks are oligonucleotides, carbohydrates, synthetic polyamides, peptide nucleic acids, antibodies, ligands, proteins, haptens, zinc fingers, aptamers, mass labels, or any combination of these.
- 43. The method of claim 1, wherein the specific binding molecule and the carrier are covalently linked.
- 44. The method of claim 1, wherein the carrier and the blocks are covalently linked.
- 45. The method of claim 44, wherein the specific binding molecule and the carrier are covalently linked.
- 46. The method of claim 1, wherein the specific binding molecule comprises a first oligonucleotide and the carrier comprises a second oligonucleotide which can hybridize to the first oligonucleotide.
- 47. The method of claim 46, wherein the first oligonucleotide is conjugated to an antibody which binds a protein.
- 48. A composition for detecting an analyte comprising a specific binding molecule, a carrier, and a block group.
- 49. The composition of claim 48, wherein the carrier is selected from the group consisting of liposomes, microparticles, nanoparticles, and branched polymer strictures.
- 50. The composition of claim 48, wherein the carrier is a liposome.
- 51. The composition of claim 50, wherein the liposomes are unilamellar vesicles.
- 52. The composition of claim 51, wherein the vesicles have an average diameter of 150 to 300 nanometers.
- 53. The composition of claim 50, wherein the liposome has an internal diameter of 200 nanometers.
- 54. The composition of claim 48, wherein the carrier is a dendrimer.
- 55. The composition of claim 54, wherein the dendrimer is contacting a macromolecule selected from the group consisting of DNA, RNA, and PNA.
- 56. The composition of claim 55, wherein the macromolecule is an oligonucleotide between 20 and 300 nucleotides in length.
- 57. The composition of claim 48, wherein the specific binding molecule is selected from the group consisting of antibodies, ligands, binding proteins, receptor proteins, haptens, aptamers, carbohydrates, synthetic polyamides, and oligonucleotides.
- 58. The composition of claim 48, wherein the specific binding molecule is a binding protein.
- 59. The composition of claim 58, wherein the binding protein is a DNA binding protein.
- 60. The composition of claim 58, wherein the DNA binding protein contains a motif selected from the group consisting of a zinc finger motif, leucine zipper motif, and helix-turn-helix motif.
- 61. The composition of claim 48, wherein the specific binding molecule is an oligonucleotide.
- 62. The composition of claim 61, wherein the oligonucleotide is between 10 and 40 nucleotides in length.
- 63. The composition of claim 61, wherein the oligonucleotide is between 16 and 25 nucleotides in length.
- 64. The composition of claim 61, wherein the oligonucleotide is a peptide nucleic acid.
- 65. The composition of claim 61, wherein the oligonucleotide forms a triple helix with the target sequence.
- 66. The composition of claim 65, wherein the oligonucleotide comprises a psoralen derivative capable of covalently attaching the oligonucleotide to the target sequence.
- 67. The composition of claim 48, wherein the specific binding molecule is an antibody.
- 68. The composition of claim 67, wherein the antibody binds a protein.
- 69. The composition of claim 48, wherein the blocks are selected from the group consisting of oligonucleotides, carbohydrates, synthetic polyamides, peptide nucleic acids, antibodies, ligands, proteins, haptens, zinc fingers, aptamers, mass labels, and any combination of these.
- 70. The composition of claim 48, wherein the blocks are peptide nucleic acids.
- 71. The composition of claim 48, wherein the blocks are capable of hybridizing specifically to an oligonucleotide reporter tag.
- 72. The composition of claim 71, wherein the length of the oligonucleotide reporter tag is between 10 and 35 nucleotides long.
- 73. The composition of claim 71, wherein the length of the oligonucleotide reporter tag is between 15 and 20 nucleotides long.
- 74. The composition of claim 48, wherein the blocks are capable of being detected by a method selected from the group consisting of nuclear magnetic resonance, electron paramagnetic resonance, surface enhanced raman scattering, surface plasmon resonance, fluorescence, phosphorescence, chemiluminescence, resonance raman, microwave, mass spectrometry, mass spectrometry electrophoresis chromatography, and any combination of these.
- 75. The composition of claim 48, wherein the blocks are capable of being detected through MALDI-TOF spectroscopy.
- 76. The composition of claim 48, wherein the specific binding molecule and the carrier are covalently linked.
- 77. The composition of claim 48, wherein the carrier and the blocks are covalently linked.
- 78. The composition of claim 77, wherein the specific binding molecule and the carrier are covalently linked.
- 79. The composition of claim 48, wherein the specific binding molecule comprises a first oligonucleotide and the carrier comprises a second oligonucleotide which can hybridize to the first oligonucleotide.
- 80. The composition of claim 79, wherein the first oligonucleotide is conjugated to an antibody which binds a protein.
- 81. The composition of claim 48, wherein the blocks are isobaric blocks.
- 82. A set of detectors comprising a plurality of detectors,
wherein each detectors comprises a specific binding molecule, a carrier, and a block group, wherein the block group comprises blocks, wherein each block group has a different composition of blocks.
- 83. The set of claim 82, wherein each block group has the same number of blocks.
- 84. The set of claim 82, wherein the block groups do not all have the same number of blocks.
- 85. The set of claim 82, wherein each block group has a different identity composition of blocks.
- 86. The set of claim 82, wherein the blocks have the same amount composition.
- 87. The set of claim 82, wherein the blocks do not all have the same amount composition.
- 88. The set of claim 82, wherein block groups that have the same identity composition of blocks have different amount compositions of blocks.
- 89. The set of claim 82, wherein the blocks comprise reporter signals,
wherein the reporter signals have a common property, wherein the common property allows the reporter signals to be distinguished or separated from molecules lacking the common property, wherein the reporter signals can be altered, wherein the altered forms of each reporter signal can be distinguished from every other altered form of reporter signal.
- 90. The set of claim 89, wherein the common property is mass-to-charge ratio, wherein the reporter signals are altered by altering their mass, wherein the altered forms of the reporter signals can be distinguished via differences in the mass-to-charge ratio of the altered forms of reporter signals.
- 91. The set of claim 90, wherein the mass of the reporter signals is altered by fragmentation.
- 92. The set of claim 90, wherein alteration of the reporter signals also alters their charge.
- 93. The set of claim 89, wherein the common property is mass-to-charge ratio, wherein the reporter signals are altered by altering their charge, wherein the altered forms of the labeled proteins can be distinguished via differences in the mass-to-charge ratio of the altered forms of reporter signals.
- 94. The set of claim 89, wherein the set comprises two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, twenty or more, thirty or more, forty or more, fifty or more, sixty or more, seventy or more, eighty or more, ninety or more, or one hundred or more different reporter signals.
- 95. The set of claim 94, wherein the set comprises ten or more different reporter signals.
- 96. The set of claim 89, wherein the reporter signals are peptides, oligonucleotides, carbohydrates, polymers, oligopeptides, or peptide nucleic acids.
- 97. The set of claim 89, wherein the reporter signals are associated with, or coupled to, specific binding molecules, wherein each reporter signal is associated with, or coupled to, a different specific binding molecule.
- 98. The set of claim 89, wherein the reporter signals are associated with, or coupled to, decoding tags, wherein each reporter signal is associated with, or coupled to, a different decoding tag.
- 99. The set of claim 89, wherein the reporter signals comprise peptides, wherein the peptides have the same mass-to-charge ratio.
- 100. The set of claim 99, wherein the peptides have the same amino acid composition.
- 101. The set of claim 100, wherein the peptides have the same amino acid sequence.
- 102. The set of claim 101, wherein each peptide contains a different distribution of heavy isotopes.
- 103. The set of claim 101, wherein each reporter signal peptide contains a different distribution of substituent groups.
- 104. The set of claim 100, wherein each peptide has a different amino acid sequence.
- 105. The set of claim 100, wherein each peptide has a labile or scissile bond in a different location.
- 106. The set of claim 89, wherein the reporter signals are coupled to the proteins or peptides.
- 107. The set of claim 89, wherein the common property allows the labeled proteins to be distinguished or separated from molecules lacking the common property.
- 108. The set of claim 89, wherein the common property is not an affinity tag.
- 109. The set of claim 108, wherein one or more affinity tags are associated with the reporter signals.
- 110. A set of block groups comprising a plurality of block groups,
wherein each block group comprises blocks, wherein the blocks comprise reporter signals, wherein the reporter signals have a common property, wherein the common property allows the reporter signals to be distinguished or separated from molecules lacking the common property, wherein the reporter signals can be altered, wherein the altered forms of each reporter signal can be distinguished from every other altered form of reporter signal.
- 111. A set of blocks comprising a plurality of blocks,
wherein the blocks comprise reporter signals, wherein the reporter signals have a common property, wherein the common property allows the reporter signals to be distinguished or separated from molecules lacking the common property, wherein the reporter signals can be altered, wherein the altered forms of each reporter signal can be distinguished from every other altered form of reporter signal.
- 112. A kit comprising a set of detectors, wherein the set of detectors comprises a plurality of detectors,
wherein each detectors comprises a specific binding molecule, a carrier, and a block group, wherein the block group comprises blocks.
- 113. The kit of claim 112 wherein the blocks comprise reporter signals,
wherein the reporter signals have a common property, wherein the common property allows the reporter signals to be distinguished or separated from molecules lacking the common property, wherein the reporter signals can be altered, wherein the altered forms of each reporter signal can be distinguished from every other altered form of reporter signal.
- 114. A mixture comprising
a set of detectors and a target sample, wherein the set of detectors comprises a plurality of detectors, wherein each detectors comprises a specific binding molecule, a carrier, and a block group, wherein the block group comprises blocks.
- 115. The mixture of claim 114 wherein the blocks comprise reporter signals,
wherein the reporter signals have a common property, wherein the common property allows the reporter signals to be distinguished or separated from molecules lacking the common property, wherein the reporter signals can be altered, wherein the altered forms of each reporter signal can be distinguished from every other altered form of reporter signal.
- 116. A method of detecting analytes, the method comprising
associating one or more detectors with one or more target samples, wherein the detectors each comprise a specific binding molecule, a carrier, and a block group, and detecting the block group, wherein the block group comprises blocks, wherein the blocks comprise reporter signals, wherein the reporter signals have a common property, wherein the common property allows the reporter signals to be distinguished or separated from molecules lacking the common property, wherein the reporter signals can be altered, wherein the altered forms of each reporter signal can be distinguished from every other altered form of reporter signal, wherein the common property is mass-to-charge ratio, wherein the reporter signals are altered by altering their mass, wherein the altered forms of the reporter signals can be distinguished via differences in the mass-to-charge ratio of the altered forms of reporter signals, wherein the mass of the reporter signals is altered by fragmentation, wherein the block group comprises ten or more different reporter signals, wherein the reporter signals comprise peptides, wherein the peptides have the same mass-to-charge ratio, wherein the peptides have the same amino acid composition, wherein the peptides have the same amino acid sequence, wherein each peptide contains a different distribution of heavy isotopes.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of U.S. Provisional Application No. 60/332,982, filed Nov. 6, 2001. Application Ser. No. 60/332,982, filed Nov. 6, 2001, application Ser. No. 09/850,539, filed May 7, 2001, and application Ser. No. 09/929,266, filed Aug. 13, 2001, are hereby incorporated herein by reference in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60332982 |
Nov 2001 |
US |